BRAIN and NERVE－神経研究の進歩74巻5号

2022年05月発行

増大特集 次の一手—神経筋疾患難治例をどのように治療するか

統合失調症に対する抗精神病薬治療中に出現した遅発性ジスキネジア—最新の知見に基づいた遅発性ジスキネジアへの対応

著者： 阪田麻友美¹ 伊東秀文¹

所属機関： ¹和歌山県立医科大学脳神経内科

ページ範囲：P.571 - P.574

文献概要

遅発性ジスキネジアはドパミン受容体遮断薬の長期使用に関連した薬剤誘発性の不随意運動で，原因薬剤の中止・変更で改善がなければ治療を行う。最も有効な薬剤は小胞モノアミン輸送体2選択的阻害薬であるが，クロナゼパム，アマンタジン，抑肝散，イチョウ葉エキスなども有効な場合がある。薬剤抵抗性の場合，ボツリヌス治療や脳深部刺激療法も選択される。精神疾患に留意しながら最適な治療を模索する必要がある。

参考文献

1）村瀬永子: ジスキネジア—薬剤誘発性運動異常症, 発作性運動異常症, その他まれなジスキネジア. 梶 龍兒（編）: 不随意運動の診断と治療 改定第2版—動画で学べる神経疾患. 診断と治療社, 東京, 2016, pp142-157

2）Ossowska K: Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol J Pharmacol 54: 299-312, 2002

3）Carbon M, Kane JM, Leucht S, Correll CU: Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry 17: 330-340, 2018

4）Inada T, Yagi G, Kaijima K, Ohnishi K, Kamisada M, et al: Clinical variants of tardive dyskinesia in Japan. Jpn J Psychiatry Neurol 45: 67-71, 1991

5）Horiguchi J, Shingu T, Hayashi T, Hayashi T, Kagaya A, et al: Antipsychotic-induced life-threatening ‘esophageal dyskinesia’. Int Clin Psychopharmacol 14: 123-127, 1999

6）厚生労働省: 重篤副作用疾患別対応マニュアル—ジスキネジア. 2009　https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1c21.pdf（最終閲覧日: 2022年2月15日）

7）Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, et al: Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: the curaçao extrapyramidal syndromes study Ⅻ. J Clin Psychiatry 78: e279-e285, 2017［doi: 10.4088/JCP.16m11049］

8）Kane JM: Tardive dyskinesia: epidemiological and clinical presentation. Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 1994

9）Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S: Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci 389: 67-75, 2018

10）Arya D, Khan T, Margolius AJ, Fernandez HH: Tardive dyskinesia: treatment update. Curr Neurol Neurosci Rep 19: 69, 2019［doi: 10.1007/s11910-019-0976-1］

11）Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, et al: Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 147: 445-451, 1990

12）Gerlach J, Rye T, Kristjansen P: Effect of baclofen on tardive dyskinesia. Psychopharmacology (Berl) 56: 145-151, 1978

13）Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S: Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 33: 271-275, 2010

14）Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM: A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 17: 88-91, 1997

15）Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, et al: Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharmacol Bio Psychiatry 22: 761-764, 2008

16）Cadet JL, Lohr JB: Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 570: 176-185, 1989

17）Zhang WF, Tan YL, Zhang XY, ChanRC, Wu HR, et al: Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72: 615-621, 2011

18）Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, et al: Vitamin E treatment for tardive dyskinesia: veterans affairs cooperative study #394 study group. Arch Gen Psychiatry 56: 836-841, 1999

19）Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, et al: Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord 15: 352-355, 2000

20）van Harten PN, Hovestadt Ad: Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord 21: 1276-1277, 2006

21）Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, et al: Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 86: 651-659, 2016